Commande rapide

CD137 / 4-1BB Protein

Description du produit: Active
Hôte d’expression: Human Cells
  • Slide 1
10041-H03H-100
10041-H03H-200
100 µg / 
200 µg / 
Add to Cart
Hôte d’expression: Human Cells
  • Slide 1
10041-H08H-50
10041-H08H-100
50 µg / 
100 µg / 
Add to Cart
Hôte d’expression: Human Cells
  • Slide 1
  • Slide 1
50811-M02H-50
50811-M02H-100
50 µg / 
100 µg / 
Add to Cart
Hôte d’expression: Human Cells
  • Slide 1
  • Slide 1
70095-D08H-100
70095-D08H-200
100 µg / 
200 µg / 
Add to Cart
Hôte d’expression: Human Cells
  • Slide 1
70095-D02H-200
70095-D02H-100
200 µg / 
100 µg / 
Add to Cart

Browse CD137 / 4-1BB Products by

CD137 / 4-1BB Domaines apparentés

CD137 / 4-1BB Voies apparentées

CD137 / 4-1BB Récapitulatif et informations sur les protéines

CD137 / 4-1BB Fond

Résumé du gène: The protein encoded by TNFRSF9 gene is a member of the TNF-receptor superfamily. This receptor contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. The expression of this receptor is induced by lymphocyte activation. TRAF adaptor proteins have been shown to bind to this receptor and transduce the signals leading to activation of NF-kappaB. [provided by RefSeq, Jul 2008]
General information above from NCBI
Structure de sous-unités: Interacts with TRAF1, TRAF2 and TRAF3. Interacts with LRR-repeat protein 1/LRR-1.
Localisation subcellulaire: Membrane; Single-pass type I membrane protein.
Spécificité tissulaire: Expressed on the surface of activated T-cells.
Similarité de séquence: Contains 4 TNFR-Cys repeats.
General information above from UniProt

CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.

CD137 / 4-1BB Autre dénomination

CD137 / 4-1BB Études apparentées

  • Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.
  • Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.
  • Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.
  • Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.
  • Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.
  • Veuillez noter : Tous les produits sont « DESTINÉS À LA RECHERCHE UNIQUEMENT ET NE SONT PAS PRÉVUS POUR ÊTRE UTILISÉS À DES FINS DE DIAGNOSTIC OU THÉRAPEUTIQUES »